Hayakawa T, Uchiyama M, Urata J, Enomoto T, Okubo J, Okawa M
Department of Psychiatry, Kohnodai Hospital, National Center of Neurology and Psychiatry, Ichikawa, Chiba, Japan.
Psychiatry Clin Neurosci. 1999 Apr;53(2):185-7. doi: 10.1046/j.1440-1819.1999.00530.x.
Ten healthy men (mean age, 33.9 years) participated in two experimental sessions cross-overed randomly in a double-blind manner: one with the placebo and another with 0.125 mg of triazolam (TRZ). Resting electroencephalography and event-related potential under oddball paradigm were recorded before the drug administration, and 1, 2, 4, 6 and 8 h after that. P300 waveforms were analyzed by peak amplitudes and 30-ms bin data. Triazolam may cause cognitive dysfunction without general sedation or apparent sleepiness, and this effect appeared 2 h, 4 h and 6 h, most prominently 6 h, after TRZ administration.